替加氟卡铂同步放化治疗锁骨上淋巴结转移食管癌  

Tegafur Combined with Carboplatin Concurrent Chemoradiation for Esophagus Carcinoma with Supraclavicular Lymph Node Metastasis

作　　者：陈辉林[1] 白旭纯 王永川[1] 谢志原[1] 

机构地区：[1]福建省安溪县医院放疗科,福建安溪362400

出　　处：《黑龙江医学》2011年第12期898-900,共3页Heilongjiang Medical Journal

摘　　要：目的探讨替加氟卡铂同步放化治疗锁骨上淋巴结转移食管癌的临床疗效。方法回顾性分析36例锁骨上淋巴结转移食管癌患者,采用钴-60常规分割放疗,总剂量60～68 Gy。化疗采用替加氟卡铂方案:CF 0.3静脉点滴,第1～5 d;替加氟750 mg/m2静脉点滴,第1～5 d;卡铂250 mg/m2静脉点滴,第1～5 d2,8 d为1周期,共用2～4周期,放疗结束后评价疗效。结果近期疗效临床有效率食管原发灶(CR+PR)为83.3%(30/36);锁骨上淋巴结(CR+PR)为63.9%(23/36);1、2、3年生存率分别为55.6%(20/36)、22.2%(8/36)、13.9%(5/36);远处转移52.8%(19/36);主要不良反应为骨髓抑制、胃肠道反应。结论同步放化疗能提高伴有锁骨上淋巴结转移的晚期食管癌患者的疗效,其毒副作用可耐受。Objective The aim of the study was to observe the clinical value of tegafur combined with carboplatin concurrent chemoradiation for esophagus carcinoma with supraclavicular lymph node metastasis.Methods 36 cases of such patients of were adopted for this study.All patients were given conventional fractionated radiation therapy with cobalt-60.Total doses of irradiation were ranged from 60 to 68 Gy.The regimen for chemotherapy was tegafur carboplatin（CF 0.3 on d1~5;tegafur 750 mg/m2 on d1~5;carboplatin 250 mg/m2 on d1~5）.A treatment cycle was 28 days and two to four cycles was given.Results The Short-term effect of CR combined with PR for primary tumor and for Supraclavicular lymph node metastasis were（30/36）83.3%,（23/36）63.9% respectively.The 1、2、4-year survival rates in the RCT group were 74.2%（46/62）,54.8%（34/62）,29%（18/62） respectively.The survival rates of the RCT group in 1 to 3y were（20/36）55.6%,（8/36）22.2%,（5/36）13.9% respectively.The main side effects were bone marrow suppression and gastrointestinal reactions.Conclusion Concurrent radiochemotherapy could improve the effect of patients with supraclavicular lymph node metastasis,and the toxicities of RCT could be tolerable.

关 键 词：食管肿瘤/放射疗法 食管肿瘤/化学疗法 

分 类 号：R730.5[医药卫生—肿瘤]